Abcodia is a clinical stage company engaged in the commercial development of novel, scientifically validated tests for the early detection of cancer. The Company’s first product is the ROCA® Test for the early detection of ovarian cancer, and is also expanding its pipeline of early detection technologies for lung, colorectal and pancreatic cancer.
Abcodia’s products are based on expertise in measuring and modelling dynamic changes over time of clinical variables including test results from serum-based markers before cancer is clinically diagnosed. The company maintains exclusive commercial access to a biobank of prospectively collected samples donated from over 200,000 individuals over a 10-year period for the purpose of studies in the early detection and screening of cancer.
Abcodia is a privately held company funded through investments from Albion Ventures, Cambridge Innovation Capital, Scottish Equity Partners and UCL Business. The company is headquartered in U.K.